FMP
Greenwich LifeSciences, Inc.
GLSI
NASDAQ
Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.
14.39 USD
0.4 (2.78%)
About
ceo
Mr. Snehal S. Patel
sector
Healthcare
industry
Biotechnology
website
https://greenwichlifesciences.com
exchange
NASDAQ
Description
Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.
CIK
0001799788
ISIN
US3968791083
CUSIP
396879108
Address
Building 14
Phone
832 819 3232
Country
US
Employee
3
IPO Date
Sep 25, 2020
Key Executives
